SCHEMBL3589289

SCHEMBL3589289

CNC(=O)c1cc(Oc2cccc(NC(=O)c3nc4cc(C(F)(F)F)ccc4[nH]3)c2)ccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.60
RAF1 P04049 12/20 0.60
KDR P35968 2/20 0.60
RET P07949 2/20 0.60
PLK4 O00444 1/20 0.60
AURKA O14965 1/20 0.60
MAPK13 O15264 1/20 0.60
JAK2 O60674 1/20 0.60
MAP4K4 O95819 1/20 0.60
ABL1 P00519 1/20 0.60
LCK P06239 1/20 0.60
FYN P06241 1/20 0.60
LYN P07948 1/20 0.60
ROS1 P08922 1/20 0.60
SRC P12931 1/20 0.60
RPS6KB1 P23443 1/20 0.60
EPHA2 P29317 1/20 0.60
TYK2 P29597 1/20 0.60
AXL P30530 1/20 0.60
FRK P42685 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13408250 0.91 KDR (0.65) BRAFRAF1KDRRETPLK4
SCHEMBL13408255 0.89 BRAF (0.49) BRAFRAF1KDRRETPLK4
SCHEMBL3597680 0.88 KDR (0.49) BRAFRAF1KDRRETPLK4
SCHEMBL3589751 0.87 KDR (0.53) BRAFRAF1KDRRETPLK4
SCHEMBL3596282 0.84 RET (0.62) BRAFRAF1KDRRETPLK4
SCHEMBL3596312 0.83 NPC1 (0.50) RAF1KDR
SCHEMBL12020953 0.83 KDR (0.63) BRAFRAF1KDRRETPLK4
SCHEMBL6425836 0.82 RET (0.66) BRAFRAF1KDRRETPLK4
SCHEMBL13408258 0.81 KDR (0.51) BRAFKDRRETMAPK14TNNI3K
SCHEMBL3021926 0.80 BRAF (0.87) BRAFRAF1KDRRETPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643991-B1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-03-12 EP disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885KDR 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.